In Brief: Endocare/Boston Scientific:
This article was originally published in The Gray Sheet
Endocare/Boston Scientific: Firms sign eight year agreement under which Boston Scientific acquires exclusive worldwide distribution rights to Endocare's Cryocare Surgical System, used for freezing and removing tissue during minimally invasive procedures. The deal includes an "initial license fee to Endocare, minimum purchase requirements and certain purchase rights following Medicare reimbursement of the prostate procedure," Endocare says. Financial terms were not disclosed. Under a previous agreement, Mentor will continue to market Cryocare in Canada...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.